Clinical Trial Data, Stock Price Movements, Financial Results, and Diagnostic Tests - Research Report on Volcano, Health Management, MAKO, Haemonetics, and Alere

NEW YORK, November 6, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Volcano Corporation (NASDAQ: VOLC), Health Management Associates Inc. (NYSE: HMA), MAKO Surgical Corp. (NASDAQ: MAKO), Haemonetics Corporation (NYSE: HAE) and Alere Inc. (NYSE: ALR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Volcano Corporation Research Report

On October 30, 2013, Volcano Corporation (Volcano) announced final results of ADVISE (Adenosine Vasodilator Independent Stenosis Evaluation) II, a prospective, double-blind, global, multicenter registry designed to investigate the diagnostic utility of the instant wave-Free Ratio (iFR) Modality in assessing the severity of coronary stenosis. According to the Company, the final results confirm earlier findings and show that the hybrid iFR/FFR (Fractional Flow Reserve) approach correctly matched an FFR-only approach in 94.2% of coronary stenosis and successfully avoided use of adenosine in 65.1% of patients. Commenting on the results, Joe Burnett, Executive Vice President and General Manager of Volcano's Functional Management Business, said, "ADVISE II is important because it shows that the retrospective performance of the iFR algorithm has now been confirmed in a controlled, prospective manner at 40 global centers with many different users. This represents the final stage in our validation of iFR compared with other physiologic indices and gives us the confidence to move forward with a series of outcome studies where iFR will contribute to clinical decision making live in the cath lab , including the SYNTAX II trial and the DEFINE family of studies." The Full Research Report on Volcano Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/14bf_VOLC]

--

Health Management Associates Inc. Research Report

On November 1, 2013, Health Management Associates Inc.'s (Health Management) stock declined 0.23%, ending the day at $12.79. Over the previous three trading sessions, shares of Health Management have declined 1.01% compared to the S&P 500 which declined 0.58% during the same period. The Full Research Report on Health Management Associates Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/9ce8_HMA]

--

MAKO Surgical Corp. Research Report

On November 1, 2013, MAKO Surgical Corp.'s (MAKO) stock rose 0.07%, ending the day at $29.83. Over the previous three trading sessions, the shares of MAKO declined 0.10% compared to the Nasdaq Composite which declined 0.77% during the same period. The Full Research Report on MAKO Surgical Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/7465_MAKO]

--

Haemonetics Corporation Research Report

On October 28, 2013, Haemonetics Corporation (Haemonetics) reported its Q2 FY 2014 financial results (period ended September 28, 2013). The Company's net revenues increased 8.1% YoY to $235.8 million during the quarter. Net income was $16.5 million or $0.32 per diluted share in Q2 FY 2014, compared to $6.5 million or $0.13 per diluted share in Q2 FY 2013. Commenting on the results, Brian Concannon, Haemonetics' President and CEO, said, "This quarter's revenue performance included a 12% increase in identified growth drivers representing over half our base revenue, offset by continued evidence of a weak U.S. market being driven by improved blood management practices. Our focus on productivity and expense management drove solid profitability gains. We are making excellent progress advancing our Value Creation & Capture initiatives, providing us the necessary flexibility to compete in this new environment." For full-year FY 2014, the Company anticipates organic revenue to grow by 0% to 2% on a reported basis. The Full Research Report on Haemonetics Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/7c61_HAE]

--

Alere Inc. Research Report

On October 29, 2013, Alere Inc. (Alere) announced that Alere Determine HIV-1/2 Ag/Ab Combo test is immediately available in US. According to the Company, the said test is the first U.S. Food and Drug Administration (FDA) approved rapid point-of-care test that detects both HIV-1/2 antibodies and HIV-1 p24 antigen, which can appear days after infection and prior to HIV-1/2 antibodies. Joe Medeiros, Director of Marketing, North America Virology Solutions at Alere, commented, "The availability of the Alere Determine Combo test will contribute measurably to public health by helping HIV-positive individuals to become aware of their HIV status earlier, thereby potentially reducing HIV transmission. Earlier diagnosis can also allow effective treatment to be started without delay." Alere informed that Alere Determine HIV1/2 Ag/Ab Combo is currently available to all health facilities and laboratories that are licensed to conduct tests of moderate complexity under the CLIA (Clinical Laboratory Improvement Amendments) program. The Company added that Alere Determine HIV-1/2 Ag/Ab Combo test is currently undergoing CLIA-waiver studies to demonstrate its ease of use, safety, and accuracy. Alere further stated that it plans to submit to the FDA its application to categorize Alere Determine HIV-1/2 Ag/Ab Combo as a CLIA-waived test in Q4 2013, in order to make it widely available in physician offices and public settings. The Full Research Report on Alere Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/5da1_ALR]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner